Taken together, these results suggest that the expression of the potential novel drug targets AIM1, ERGIC1, TMED3, and TPX2 is promoted by ERG oncogene and androgens in cultured prostate cancer cells. This evidence concerns the gene TMED3 and Familial prostate cancer.